This Pharma Stock Is Given A ‘Buy' By ICICI Direct For 21% Gains In 12 Months

ICICI Direct has recommended a ‘Buy' on the scrip of IPCA Laboratories for 12 months period with a target price of Rs. 2490. This implies an upside of 20.69 percent from the current price level of Rs. 2063 per share.

from Tax Saving Investments | Tax Saving Tips & News | Income Tax India – Oneindia Money https://ift.tt/3oWERZh
via IFTTT

Post a Comment

Please Select Embedded Mode To Show The Comment System.*

Previous Post Next Post